Adrian N. Hobden, PhD matriculated from Churchill College, Cambridge in 1972. He has a BA in natural sciences (biochemistry) and a PhD in molecular biology from the University of Leicester. After post-doctoral studies on Vitamin D with the UK Medical Research Council in Cambridge, Adrian was recruited in 1981 to Glaxo (now GSK) to establish a molecular biology/ genetics group. He worked on the discovery of pharmaceuticals for the treatment of HIV, fungal infections, cardiovascular diseases, CNS diseases and cancer. In 1996, Adrian moved to Research Triangle Park, North Carolina to manage all of Glaxo’s biotechnology interactions and in 1998 was recruited to establish Myriad Pharmaceuticals in Salt Lake City, UT. Subsequently, he became CEO of Myrexis, a public company with about 200 employees. Adrian is now CEO of Cerespir, Inc., a company dedicated to finding treatments for neurodegenerative diseases.